• Axial3D

  Led · Equity · Jul 2019

  Axial3D offers a cloud-based, 510(k) cleared segmentation platform that uses AI algorithms to convert CT and MRI DICOM data into accurate 3D visualizations, printable files, and patient-specific anatomic models. Its tools reduce the time, specialized skill and cost typically required to produce 3D printed models used for pre-surgical planning, diagnostics, education, training and medical device development. The company’s software has been validated with Stratasys printers to produce biomechanically realistic models for multiple specialties. Axial3D intends to expand accessibility of patient-specific 3D printing for hospitals and medical device manufacturers through joint offerings with Stratasys to help scale those programs. The company highlighted plans to discuss the collaboration at RSNA 2022. Axial3D is presented in the release from Belfast, Northern Ireland and Rehovot, Israel. axial3D produces precise patient-specific 3D medical models generated from CT, MRI and PET data to improve pre-operative planning and personalize healthcare. The company specializes in medical 3D printing to advance surgical standards and efficiency. Led by CEO Daniel Crawford, axial3D operates out of Belfast, UK and Claymont, Del. It recently closed a $3M funding round to support its growth. axial3D plans to use the funds to expand its machine learning team, which builds automated algorithms. The company also intends to grow into the U.S. market by opening a regional office. axial3D is a Belfast, UK-based web-based technology company focused on 3D printing in healthcare. It creates precise 3D models generated from patient CT, MRI and PET data to aid diagnosis and enhance pre-operative planning. Its 3D-printed models are used by prominent consultants from the NHS and private healthcare sectors across disciplines including orthopaedics, oncology, oral and maxillofacial, trauma and cardiac surgery. The company raised a second close of seed funding, which now totals £530K. axial3D plans to use the funds to further develop its axial3D insight. Techstart NI and investor Patrick Hurst MBE are named backers, with Hurst joining the board as Chairperson.

• Sonarworks

  Participated · Series A · May 2019

  Sonarworks builds next-generation audio applications for professional studios and consumer devices, with its products used in roughly 70,000 studios worldwide. Founded in 2012 in Riga, the company gained attention after unveiling its Reference 3 product suite at NAMM in 2015. In early 2020 Sonarworks launched SoundID, a machine learning–based app that creates customized sound profiles via a hearing test. The firm has signed licensing agreements with partners and is expanding its licensing operations. Sonarworks plans to deepen its presence in the U.S. and enter Asian markets as part of a broader goal to bring better audio to over 1 billion devices. Financially, the company has raised a total of $13.8 million to date, including its latest $6 million round. Sonarworks develops digital sound calibration and personalization software that combines device-level calibration with individualized hearing profiles. The company maintains a database of more than 10,000 measured sound devices and uses AI-based technologies to precisely map individual hearing and sound preferences. By combining digital adjustment of the sound device and individual hearing data, Sonarworks aims to deliver a personalized sound experience for every individual on every device. It serves customers in over 170 countries. Founded in 2012 and led by CEO Helmuts Bems, the company plans to use new funding to develop its consumer calibration and personalization products and expand its market presence in key regions. The article notes a recent financing event that supports these product and expansion plans. Sonarworks builds software that eliminates sound shortcomings in speakers and headphones, including its Reference 3 calibration product used in professional audio. More than 5,000 studios worldwide use Reference 3, from home studios to recording studios where artists such as Taylor Swift, Beyonce and Lady Gaga record. The company has received industry recognition, winning Sound On Sound's Best Audio Product in 2016 and an Innovation Award from MusicTech. The fresh €700,000 from the third investment round will be used to develop a new product aimed at a wider consumer market to let listeners hear music as it was recorded regardless of playback device. Financially, Sonarworks has attracted €1.5 million in venture capital to date and reported that sales exceeded costs at the beginning of the year. The idea dates to 2012 and the company was officially registered in 2013.

• Lightspace Labs

  Participated · Equity · May 2017

  Lightspace Technologies is an AS HansaMatrix–associated DeepTech company focused on multi-plane volumetric real-time 3D image displays. Its product range includes large-screen front-view 3D displays, bench-top surface 3D displays, and a recently released multi-plane stereo 3D head-mounted VR/AR display targeted at professional audiences. The company supplies technology to medical, industrial, and defense customers and licenses its technology to Tier‑1 augmented reality automotive and consumer OEMs. A financing package from AS HansaMatrix, backed by the European Investment Bank, was announced to support acquisition of technological equipment and further R&D. Planned uses also include development of fabrication and industrialization processes for key photonics elements. The company emphasized scaling production and commercialization efforts tied to those investments. SIA Lightspace Technologies is an AS HansaMatrix-associated company that undertook a share-capital increase in May 2018. The company issued 7,186 new shares; after the increase share capital amounts to €13,871 and consists of 13,871 shares. The increase was effected via a mix of contributions in kind (equity in SIA EUROLCDS) and cash, with KS BaltCap Latvia Venture Capital Fund, AS HansaMatrix and Ilmārs Osmanis subscribing new shares. Following the transaction Lightspace acquired 76.12% of its main supplier SIA EUROLCDS, a move described as ensuring an optimal business structure and reducing supply-chain risks. Ownership of Lightspace after the increase is split among KS BaltCap (44.08%), AS HansaMatrix (39.99%), KS AIF Imprimatur Capital Technology Venture Fund (9.34%), Ilmārs Osmanis (3.60%) and KS AIF Imprimatur Capital Seed Fund (2.99%). The transaction included sizable in-kind valuations of EUROLCDS equity and a cash contribution from AS HansaMatrix, reflecting a strategic consolidation rather than a public fundraising round. LightSpace Technologies is a Riga, Latvia-based developer of optically deep volumetric 3D image display technologies. Its technology produces optically deep volumetric 3D images with primary uses in medicine, scientific visualization and AR/MR applications. The company raised €800k in funding from backers that included JSC HansaMatrix and Imprimatur Capital Technology Venture Fund. LightSpace intends to use the funds to continue development of its technologies and to develop customer applications. The product is positioned for specialized professional, medical and augmented/mixed reality markets. The announcement was reported by FinSMEs on 09/05/2017.

• Iceni

  Participated · Equity · May 2016

  Iceni Pharmaceuticals launched to develop repurposed and reformulated cancer therapies, using established drugs in new combinations to reduce cost and risk and accelerate patient access. Its lead product, Cilcane® (cilengitide), is being repurposed as a first-in-class treatment for multiple myeloma and is reported to have an excellent safety profile and a novel mechanism of action. Preclinical studies conducted by Iceni indicate Cilcane® is effective as a combination therapy with proteasome inhibitors such as bortezomib, and the company believes the approach may extend to breast and other cancers. Iceni holds a broad intellectual property portfolio covering formulation and methods of use for Cilcane® and has appointed a scientific advisory board including former Merck Serono executives and leading myeloma researchers. Cilengitide was previously involved in over 30 clinical trials, including extensive Phase III testing at Merck Serono, though monotherapy development in glioblastoma was terminated in 2013. The company plans a Phase II safety/efficacy trial of Cilcane® starting in 2017 for relapsed refractory patients who have received prior proteasome inhibitor therapy.

• BranchTrack

  Participated · Seed · Mar 2016

  BranchTrack offers a simulation platform that lets companies build their own corporate training without expensive custom development. The product is positioned to replace agency-built simulations by enabling impactful, ready-to-use training at a fraction of the cost. Its software is already used in more than 1,500 companies worldwide, including paying customers such as KPMG, Pearson, Mary Kay, Slack, Johnson & Johnson and PwC. BranchTrack won the E-learning Award 2015 and was named Best Startup at the How To Web conference, receiving a $10,000 prize. The company plans to release significant software improvements, expand sales activity and introduce new sales channels. It aims to reach a €100k monthly recurring revenue (MRR) within the next 12–18 months.

No current team members are available.